FDA NDA · NDA020610

COLAZAL

Sponsor: VALEANT PHARMS INTL

What this page does not claim

A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.

APPLICATION
NDA020610
TYPE
NDA
ORIGINAL APPROVAL
2000-07-18
LATEST ACTION
2026-10-14
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

COLAZAL · ReferencePrescription
BALSALAZIDE DISODIUM 750MG · CAPSULE · ORAL

Approval history

2026-10-14Labeling · Supplement 27 · standard — Letter ↗AP
2023-10-24Labeling · Supplement 26 · standard — Label ↗AP
2022-11-16Labeling · Supplement 25 · standard — Letter ↗AP
2021-11-01Labeling · Supplement 24 · standard — Letter ↗AP
2020-10-01Labeling · Supplement 23 · standard — Letter ↗AP
2019-06-21Labeling · Supplement 21 · standard — Letter ↗AP
2015-01-05Manufacturing (CMC) · Supplement 20 · standardAP
2014-03-05Manufacturing (CMC) · Supplement 19 · standardAP
2008-07-09Labeling · Supplement 18 · standard — Letter ↗AP
2007-11-02Labeling · Supplement 17 · standard — Label ↗AP
2006-12-20Efficacy · Supplement 16 · priority — Pediatric Clinical Pharmacology Review ↗AP
2006-09-21Labeling · Supplement 14 · standard — Label ↗AP
2006-03-10Manufacturing (CMC) · Supplement 13 · standard — Letter ↗AP
2002-06-18Labeling · Supplement 1 · standard — Letter ↗AP
2002-02-07Manufacturing (CMC) · Supplement 2 · standardAP
2000-07-18Type 1 - New Molecular Entity · Original · standard — Pediatric Written Request ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →